China-developed COVID-19 Vaccine Phase 3 Clinical Trial in UAE

[Asia Economy Beijing=Special Correspondent Park Sun-mi] The coronavirus vaccine developed by China has entered Phase 3 clinical trials in the United Arab Emirates (UAE), Global Times reported on the 24th.

The newspaper explained that this is the first overseas clinical trial of a Chinese-made vaccine and an important step that could benefit everyone facing the threat of COVID-19 spread.

The vaccine developed by China National Pharmaceutical Group (Sinopharm) has already been tested on over 1,000 people in China and demonstrated safety without side effects. Sinopharm stated that the clinical trials in the UAE are being conducted together with Group 42 in Abu Dhabi, and that vaccines that have passed Phase 3 clinical trials can be immediately sold on the market.

Sinopharm already has vaccine production facilities in place. In April, Sinopharm announced that its Beijing and Wuhan laboratories each have the capacity to produce 120 million and 100 million doses of the vaccine annually, respectively.

This content was produced with the assistance of AI translation services.